skip to main content
Refined by: List of all Versions remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Material Type:
Article
Add to e-Shelf

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial

Ferrari, Michel ; Diener, Hans ; Ning, Xiaoping ; Galic, Maja ; Cohen, Joshua ; Yang, Ronghua ; Mueller, Matthias ; Ahn, Andrew ; Grozinski-Wolff, Melissa ; Janka, Lindsay ; Ashina, Messoud

The Lancet, Sep 21, 2019, pp.1030-1040 [Peer Reviewed Journal]

© ProQuest LLC All rights reserved

No full-text

2
Material Type:
Article
Add to e-Shelf

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial

Ferrari, Michel D ; Diener, Hans Christoph ; Ning, Xiaoping ; Galic, Maja ; Cohen, Joshua M ; Yang, Ronghua ; Mueller, Matthias ; Ahn, Andrew H ; Schwartz, Yael Carmeli ; Grozinski - Wolff, Melissa ; Janka, Lindsay ; Ashina, Messoud

The Lancet, Sept 21, 2019, Vol.394(10203), p.1030 [Peer Reviewed Journal]

Cengage Learning, Inc.

No full-text

3
Material Type:
Article
Add to e-Shelf

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial

Ferrari, Michel D ; Diener, Hans Christoph ; Ning, Xiaoping ; Galic, Maja ; Cohen, Joshua M ; Yang, Ronghua ; Mueller, Matthias ; Ahn, Andrew H ; Schwartz, Yael Carmeli ; Grozinski-Wolff, Melissa ; Janka, Lindsay ; Ashina, Messoud

The Lancet, Sept 21, 2019, Vol.394(10203), p.1030 [Peer Reviewed Journal]

Cengage Learning, Inc.

No full-text

4
Material Type:
Article
Add to e-Shelf

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial

Ferrari, Michel D ; Diener, Hans Christoph ; Ning, Xiaoping ; Galic, Maja ; Cohen, Joshua M ; Yang, Ronghua ; Mueller, Matthias ; Ahn, Andrew H ; Schwartz, Yael Carmeli ; Grozinski-Wolff, Melissa ; Janka, Lindsay ; Ashina, Messoud

Lancet (London, England), 21 September 2019, Vol.394(10203), pp.1030-1040 [Peer Reviewed Journal]

MEDLINE/PubMed (U.S. National Library of Medicine)

No full-text

5
Material Type:
Article
Add to e-Shelf

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.

Ferrari, Michel D ; Diener, Hans Christoph ; Ning, Xiaoping ; Galic, Maja ; Cohen, Joshua M ; Yang, Ronghua ; Mueller, Matthias ; Ahn, Andrew H ; Schwartz, Yael Carmeli ; Grozinski-Wolff, Melissa ; Janka, Lindsay ; Ashina, Messoud Ferrari, Michel D (correspondence author) ; Ferrari, Michel D (record owner)

Lancet (London, England), September 21, 2019, Vol.394(10203), pp.1030-1040 [Peer Reviewed Journal]

© ProQuest LLC All rights reserved

No full-text

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Searching Remote Databases, Please Wait